First AD

Second AD

EHA 2024 Future Directions in Lower-Risk MDS Treatment: Emerging Data, Approvals, and Guideline Updates   

Video content above is prompted by the following

What does the future of lower-risk MDS treatment look like?

Following the latest approvals, guideline updates, and emerging data:

How does this impact your future treatment strategies?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 

Peer Exchange

The expert panel explores the future landscape of lower-risk myelodysplastic syndrome treatment, considering recent approvals and emerging clinical data. 